Filters: Br��u-2006 is   [Clear All Filters]
Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8):556-562.
Alvarez D, Dieterich D, Brau N, Moores L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006;13:683-689.
American College of Cardiology Foundation and American Heart Association, Inc. Methodology manual and policies from the ACCF/AHA task force on practice guidelines, Accessed June 13, 2019.; 2010.
Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46(12):1852-1858.
Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359-365.
Aniszewska M, Kowalik-Mikolajewska B, Pokorska-Spiewak M, Marczynska M. Anti-HCV testing as a basic standard of monitoring HCV mother-to-child infection: advantages and disadvantages of the method. Przegl Epidemiol. 2012;66:341-345.
Ankrom W, Sanchez RI, Yee KL, et al. Investigation of pharmacokinetic interactions between doravirine and elbasvir-grazoprevir and ledipasvir-sofosbuvir. Antimicrob Agents Chemother. 2019;63(5):e02491-18.
Apers L, Vanden-Berghe W, De Wit S, et al. Risk factors for HCV acquisition among HIV-positive MSM in Belgium. J Acquir Immune Defic Syndr. 2015;68(5):585-593.
Aqel B, Wijarnpreecha K, Pungpapong S, et al. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients. J Hepatol. 2021;74(4):873-880.
Arai Y, Noda K, Enomoto N, et al. A prospective study of hepatitis C virus infection after needlestick accidents. Liver. 1996;16(5):331-334.
Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49(3):739-744.
Araujo AC, Astrakhantseva IV, Fields HA, Kamili S. Distinguishing acute from chronic hepatitis C virus (HCV) infection based on antibody reactivities to specific HCV structural and nonstructural proteins. J Clin Microbiol. 2011;49(1):54-57.
Aronson I, Bennett A, Marsch LA, Bania TC. Mobile technology to increase HIV/HCV testing and overdose prevention/response among people who inject drugs. Front Public Health. 2017;5:217.
Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199-2207.
Artenie AA, Cunningham EB, Dore GJ, et al. Patterns of drug and alcohol use and injection equipment sharing among people with recent injection drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies [truncated]. Clin Infect Dis. 2020;70(11):2369-2376.
Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57(Suppl 2):S80-S89.
Asselah T, Bourgeois S, Pianko S, et al. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int. 2018;38(3):443-450.
Asselah T, Hezode C, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. The Lancet Gastroenterology & Hepatology. 2016;1(1):25 - 35. Available at:
Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417-426.
Asselah T, Hassanien T, Qadish RB, al. et. A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis. Journal of Hepatology. 2015;62(S861).